anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: HDV leads to the most severe form of viral hepatitis; however, the prevalence of HDV is not well understood. Using real-world data from the All-Payer Claims Database, this study estimates the prevalence of HBV/HDV infection among the chronic HBV population and describes patient/clinical characteristics for adults with HBV/HDV infection in the United States.
APPROACH AND RESULTS: Adults (≥18 years) with ≥1 inpatient claim or ≥2 outpatient claims for HDV infection or HBV in the All-Payer Claims Database from January 1, 2014, to December 31, 2020, were identified. HDV prevalence was calculated as the proportion of patients with HBV/HDV infection among total patients with HBV infection. Patient characteristics, socioeconomic status, advanced liver complications (eg, cirrhosis, HCC), and comorbidities were assessed. A total of 6719 patients were diagnosed with HBV/HDV among 144,975 with HBV and 12 months of continuous data, for a prevalence of 4.6%. At diagnosis, 31.7% of patients with HBV/HDV had advanced liver complications, including compensated cirrhosis (16.3%) and decompensated cirrhosis (10.4%). Diabetes (50.5%), hypertension (49.8%), and HIV infection (30.9%) were the top 3 comorbidities.
CONCLUSIONS: In a large database capturing approximately 80% of the US-insured population, HBV/HDV infection prevalence was 4.6% among adults infected with HBV. Patients infected with HDV had high rates of baseline liver complications and other comorbidities at the time of diagnosis, suggesting potentially delayed diagnosis and/or treatment. Earlier identification of HBV/HDV infection among the population with HBV may provide opportunities to improve linkage to care and treatment, thereby reducing the risk of liver-related morbidity and mortality.
OBJECTIVE: To determine reasons for horses to have neck radiographs performed, the incidence of transposition of the ventral lamina of C6 onto C7 (TC67), and the final diagnoses for all horses. Our hypotheses were to find a similar incidence of TC67, as has been previously reported, and an increased incidence of neck pain and dysfunction in horses with TC67.
ANIMALS: 135 horses.
METHODS: Retrospective observational study. Medical records of 135 horses with cervical vertebral column radiographs between 2020 and 2022 were assessed. Patient signalment, reasons for radiographs, radiographic findings, and diagnoses were analyzed. The Shapiro-Wilk test was used for normality determination. Nonparametric tests were used to analyze data.
RESULTS: 20% of horses were diagnosed with TC67. Significantly more horses with TC67 were warmblood horses (63%); TC67 was found in 28% of warmblood horses. There was no significant difference in signalment or whether horses were in work between the groups, although significantly more horses with TC67 performed in English disciplines (71%). No differences in reasons for examination or final diagnoses of neurologic disease, cervical orthopedic disease, or lameness were present between groups. In horses with neck pain, TC67 was significantly more common (31%) than in horses without (18%).
CLINICAL RELEVANCE: Our results indicated that TC67 occurs more in warmblood horses. In the small group of horses with neck pain reported, TC67 was more commonly seen than in those without. Given the complexity of this region and the paucity of studies exploring neck pain and neck biomechanics, we suggest the need for standardized prospective studies.
We present a patient with a post-pneumonectomy empyema refractory to surgical debridement and systemic antibiotics. The patient initially presented with a bronchopleural fistula and pneumothorax secondary to tuberculosis (TB) destroyed lung, which required a pneumonectomy with Eloesser flap. Ongoing pleural infection delayed the closure of the Eloesser flap, and thoracoscopic inspection of his chest cavity revealed a green, mucous biofilm-like structure lining the postpneumonectomy pleural cavity. Cultures identified pan-susceptible Pseudomonas aeruginosa. Despite debriding this biofilm-like structure and administering systemic antibiotics, the patient continued to show persistent signs of infection and regrowth of the film. We employed a novel approach to dissolve the biofilm-like structure using intrapleural dornase alfa followed by intrapleural antibiotic washes. After 3 weeks of daily washes, repeat inspection demonstrated the biofilm-like structure had completely resolved. Resolving the pseudomonas biofilm-like structure allowed permanent closure of his chest without further need for systemic antibiotics. At follow up 3 months later, he showed no sequalae. This treatment option can be an important adjunct to improve likelihood of chest closure in patients with post-pneumonectomy empyema that resists standard treatment options due to biofilm formation.
Interleukin 31 (IL-31) is a proinflammatory cytokine, mainly secreted by Type II helper T cells. It signals through a heterodimeric receptor complex composed of IL-31 receptor α and oncostatin-M receptor β chain. The hallmark feature of IL-31, in its pathological role, is its ability to induce pruritus in mammals. Pruritus is a common symptom and major reason of morbidity in cancer patients, compromising their quality of life. Although, IL-31 is differentially expressed in different tumor types and could promote or inhibit cancer progression, high expression of IL-31 is a contributing factor to advanced stage tumor and severity of pruritus. The simultaneous existence of pruritus and cancer could either result from the aberrations in common proteins that co-exist in both cancer and pruritus or the therapeutic treatment of cancer could indirectly induce pruritus. Although the biology of IL-31 has predominantly been described in skin diseases such as atopic dermatitis and other inflammatory diseases, the precise role of IL-31 in the tumor biology of different cancer types remains elusive. Herein, we summarize the current understanding on the role of this cytokine in the pathogenesis of different cancers.
After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
PURPOSE: A drug delivery material comprising pH-sensitive alginate/bentonite hygrogel ingredient is provided to release drug under the weak base condition and to control drug release rate. CONSTITUTION: A pH-sensitive alginate/bentonite hygrogel composition is prepared by mixing bentonite to alginate. The alginate and bentonite are contains in 30-90 weight% and 10-70 weight%, respectively. The effective amount of BSA(bovine serum albumin) is released at pH7.4-9.2. The alginate is a linear copolymer containing 1-4-linked β-D-mannuroic acid and alpha-L-guluronic acid. The bentonite is montmorillonite, beidellite, or nontronite. A pharmaceutical composition contains a protein for trauma and the pH-sensitive alginate/bentonite hygrogel composition.
Cardiopulmonary arrest or sudden death occurred in 15 (3%) of 538 patients treated with PORTRAZZA plus gemcitabine and cisplatin as compared to 3 (0.6%) of 541 patients treated with gemcitabine and cisplatin alone in Study 1. Twelve of the fifteen patients died within 30 days of the last dose of PORTRAZZA and had comorbid conditions including history of coronary artery disease (n=3), hypomagnesemia (n=4), chronic obstructive pulmonary disease (n=7), and hypertension (n=5). Eleven of the 12 patients had an unwitnessed death. Patients with significant coronary artery disease, myocardial infarction within 6 months, uncontrolled hypertension, and uncontrolled congestive heart failure were not enrolled in Study 1. The incremental risk of cardiopulmonary arrest or sudden death in patients with a history of coronary artery disease, congestive heart failure, or arrhythmias as compared to those without these comorbid conditions is not known. 

Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium prior to each infusion of PORTRAZZA during treatment and after PORTRAZZA administration for at least 8 weeks after the last dose. Withhold PORTRAZZA for Grade 3 or 4 electrolyte abnormalities; subsequent cycles of PORTRAZZA may be administered in these patients once electrolyte abnormalities have improved to Grade ≤2. Replete electrolytes as medically appropriate [see Boxed Warning and Warnings and Precautions (5.2)].
A latent space is defined to represent sequences using training data and a machine-learning model. The training data identifies sequences of molecules and binding-approximation metrics that characterizes whether the molecules bind to a particular target and/or that approximate an extent to which the molecule is more likely to bind to the particular target than some other molecules. Supplemental training data is accessed that identifies other sequences of other molecules and binding affinity scores quantifying binding strengths between the molecules and the particular target. Projections of representations of the other sequences in the supplemental training data are projected in the latent space using the binding affinity scores. An area or position of interest within the latent space is identified based on the projections. A particular sequence represented within or at the area or position of interest or at the position of interest is identified for downstream processing.
Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m\^2/day 5 days/week during RT, and irinotecan 50 mg/m\^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m\^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 plus 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m\^2 IV over 2 hours Day 1) .
The method involves acquiring image data (BD) at modality, where the image data comprise meta data e.g. patient identification number, and pixel data. Partial metadata in the metadata are marked. The metadata acquired by satellites (S1-S4) are locally stored in a local database (lokDB). The metadata stored in the local database are completely and centrally replicated in a central database (zentDB). The marked partial metadata are partially and automatically replicated from the central database to the local database in a decentralized manner to provide the image data to the satellites. Independent claims are also included for the following: (1) a computer program product comprising instructions for performing a method for storing and providing medical image data (2) a system for storing medical image data in a computer-based clinical facility.
The invention relates to the technical field of medicaments. Dimethyldiguanide belongs to a biguanides oral hypoglycemic medicament and is widely applied to pharmaceutical therapy of type 2 diabetes. The invention aims at providing a novel application of the dimethyldiguanide and particularly an application of the dimethyldiguanide in preparation of medicaments for preventing or treating the hepatocellular carcinoma. According to the application disclosed by the invention, the restriction effect of the dimethyldiguanide on the hepatocellular carcinoma is found by research from two aspects, namely, cell culture in vitro and animal experiment in vivo. Experiments find that the dimethyldiguanide has the capabilities of restricting proliferation and clone formation of a hepatocellular carcinoma cell line and causing the cell cycle arrest and apoptosis increase of the hepatocellular carcinoma cell line, and also has the capability of enhancing the hepatocellular carcinoma resisting effect of chemotherapeutics when combined with the chemotherapeutics, such as cis-platinum, doxorubicin and the like. The invention provides the novel application of the dimethyldiguanide and also provides a novel concept for prevention and treatment of the hepatocellular carcinoma.
Skin-to skin care by mother, kangaroo care, breastfeeding policy plus massage therapy are made by the mothers until hospital discharge. After discharge, they receive standard follow up care plus orientation for a continuous global simulation at home (total of 10 home visits independently of the standard evaluation and care that will be performed; visits promoting guidance and supervision sessions).
Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
PURPOSE: An anticancer composition using siRNA is provided to suppress Hif1alpha expression and to suppress cancer cell proliferation and metastasis. CONSTITUTION: A double strand siRNA of 15-30 bp targets mRNA corresponding to one selected from bases of sequence numbers 2, 3, and 5-14. The siRNA also targets mRNA corresponding to a base of sequence number 6, 10, or 12. The siRNA has a nucleotide sequence of siRNA 1, siRNA 2, siRNA 4-siRNA 13, or siRNA 18-siRNA 20. An expression vector contains the siRNA. The expression vector is a plasmid, adeno-associated virus vector, retrovirus vector, vaccinia virus vector, or oncolytic adenovirus vector. An anticancer composition contains the siRNA in a complex form together with a nucleic acid delivery system.
PCT No. PCT/JP82/00152 Sec. 371 Date Sep. 29, 1982 Sec. 102(e) Date Sep. 29, 1982 PCT Filed May 4, 1982 PCT Pub. No. WO82/03861 PCT Pub. Date Nov. 11, 1982.Aniline derivatives of the formula:  <IMAGE> wherein R0, R1 and R2 are the same or different and each is a hydrogen atom, a halogen atom, a nitro group, an amino group, a carboxy group, a cyano group, a hydroxy group, a sulfonamido group, a lower alkyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkanoyl group, a lower alkylamino group, a lower alkylthio group, a lower alkanoylamino group or a group of the formula  <IMAGE>  wherein R5 and R6 are the same or different and each is a hydrogen atom, a lower alkyl group or a C3 to C8 cycloalkyl group or together with the nitrogen atom a morpholino, piperidino, piperazino or pyrrolidino group; R3 is a cyano group, a nitro group, a halogen atom, a lower alkyl group or a lower alkoxy group; m is an integer of 1 to 3; R4 is a hydrogen atom or a lower alkyl group; and A is a lower alkylene group. The derivatives are useful as cardiotonics.
Signs and Symptoms

In acute acetaminophen overdosage, dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur. Plasma acetaminophen levels > 300 mcg/mL at 4 hours after oral ingestion were associated with hepatic damage in 90% of patients; minimal hepatic damage is anticipated if plasma levels at 4 hours are < 150 mcg/mL or < 37.5 mcg/mL at 12 hours after ingestion. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis, and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post- ingestion.

Treatment

If an acetaminophen overdose is suspected, obtain a serum acetaminophen assay as soon as possible, but no sooner than 4 hours following oral ingestion. Obtain liver function studies initially and repeat at 24-hour intervals. Administer the antidote N-acetylcysteine (NAC) as early as possible. As a guide to treatment of acute ingestion, the acetaminophen level can be plotted against time since oral ingestion on a nomogram (Rumack-Matthew). The lower toxic line on the nomogram is equivalent to 150 mcg/mL at 4 hours and 37.5 mcg/mL at 12 hours. If serum level is above the lower line, administer the entire course of NAC treatment. Withhold NAC therapy if the acetaminophen level is below the lower line.

For additional information, call a poison control center at 1-800-222-1222.
1,204,117. Tampons or suppositories. SYNTEX CORP. 7 Sept., 1967 [8 Sept., 1966], No. 40261/66. Heading A5R. A tampon for the ear of an animal carries a pharmaceutical preparation which effects the action of the animals reproductive organs when the tampon is inserted into the animals auditory canal and the tampon may be formed with end portions of uniform circular crosssection and an intermediate portion of reduced cross-section. The tampon may also have a conical end (Figures 1, 3, not shown) or a bulbous end (Figure 2, not shown) and is formed from natural or synthetic fibres or rubbers, polyurethane, polystyrene, cellulose, or wax or paraffin. The tampon may be lubricated with wax or oil and suitable pharmaceutical preparations comprising steroidal progestogens are listed.
The invention relates to medicinal equipment and is useful in physiotherapy for controlling the functions of biological objects. 
     A method for capturing the changes induced by the action of acoustic and electromagnetic fields of a biological medium using a crystal whose structure comprises at least one semiconductor junction is offered. The crystal is positioned on an insulating plate which is in direct contact with the biological medium, and the changes in the crystal structure are captured by means of exposing the semiconductor junction thereof to a cut-off polarity electric pulse. A method for duplicating the changes that occurred in the initial crystal structure in a duplicate crystal structure is  characterized in that  both crystals are positioned on one face of a water-filled hollow insulating cartridge; then the semiconductor junction of the initial crystal is repeatedly exposed to the action of a straight-polarity reproduction pulse, after which the semiconductor junction of the duplicate crystal is exposed to the action of a capture cut-off polarity pulse. Various methods of affecting a biological object by crystals with changed structure; a device for capturing the changes induced by the action of acoustic and electromagnetic fields of a biological medium in an initial crystal structure; a device for duplicating the changes that occurred in an initial crystal structure in a duplicate crystal structure; a device for causing an affect on a biological object comprising an exposure source in the form of a crystal in whose structure the changes induced by the action of acoustic and electromagnetic fields of a biological medium are captured. Ind. cl. 15; dep. cl. 21; IIl. 13.
Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
A vaccinal efficacy augmentor comprises an IgA production promoter having an IgA production promoting effect as its effective component. The promoter is able to augment the efficacy of pathogenic virus vaccines. When administered with vaccines which contain bacteria or bacilli or virus antigens and which have the purpose of inducing immunity against infectious diseases, the IgA production promoter stimulates IgA producing cells such as Peyer's patch cells to promote secretory IgA production. Eventually, the production of an antibody against the antigen in the vaccine is augmented to well induce protective immunity and augment the efficacy of the vaccine. In addition, the augmentor can suppress side effects of the vaccine. The efficacy augmenting foods comprising the promoter.
Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. Placebo will be administered at week 24, and at week 28.
A method for determining a next hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosage for a first patient using a patient HIF-PHI model is provided. The method includes obtaining population patient data indicating HIF-PHI dosages and hemoglobin measurements for the patients. Then, virtual patient avatars are generated based on the population patient data. Each of the virtual patient avatars indicates a set of personalized model parameters for a HIF-PHI model. A plurality of HIF-PHI models are determined for the virtual patient avatars. Using the HIF-PHI models, one or more HIF-PHI treatment schemes for administering the HIF-PHI dosages is determined. Subsequently, the HIF-PHI treatment schemes along with a hematocrit and/or hemoglobin concentration for a patient are used to determine a next HIF-PHI dosage for the patient, and the next HIF-PHI dosage is administered for the patient.
PURPOSE:To enable easy sepn. operation of both components by using a copolymer of styrenes having the structure expressed by the specific formula and alpha,beta-unsatd. dicarboxylic diester. CONSTITUTION:A polymer for liquid sepn. is constituted as the copolymer of the styrene having the structure expressed by the formula (R1, R2 are H or alkyl group of 1-3C, R3, R2 are an alkyl group or aryl group of 1-18C, m=0.2-5.0, n=3-200) and the alpha,beta-unsatd. dicarboxylic diester. The polymer for liquid sepn. which is finely adjusted in viscosity and specific gravity freely in a broad range to meet the viscosity of the liquid to be separated, the specific gravities of the two components in the liquid and the specific gravity difference thereof is thereby easily produced and the sepn. operation of the two components is made easy.
Inform women of childbearing potential that tacrolimus can harm the fetus. Instruct male and female patients to discuss with their healthcare provider family planning options including appropriate contraception. Also, discuss with pregnant patients the risks and benefits of breastfeeding their infant [see Use in Specific Populations (8.1, 8.2, 8.3)].

Encourage female transplant patients who become pregnant and male patients who have fathered a pregnancy, exposed to immunosuppressants including tacrolimus, to enroll in the voluntary Transplantation Pregnancy Registry International. To enroll or register, patients can call the toll free number 1-877-955-6877 or https://www.transplantpregnancyregistry.org/[see Use in Specific Populations (8.1)].

Based on animal studies, tacrolimus may affect fertility in males and females [see Nonclinical Toxicology (13.1)].